Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R).

被引：0
|
作者：
Forde, Patrick M.
Nowak, Anna K.
Hughes, Brett Gordon Maxwell
Kok, Peey Sei
Brown, Chris
Sun, Zhuoxin
Anagnostou, Valsamo
O'Byrne, Ken
Yip, Sonia
Cook, Alistair
Lesterhuis, Willem Joost
Pavlakis, Nick
Brahmer, Julie R.
Kindler, Hedy L.
Tsao, Anne S.
Zauderer, Marjorie Glass
Ramalingam, Suresh S.
Stockler, Martin R.
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA
[2] Univ Western Australia, Nedlands, WA, Australia
[3] Prince Charles Hosp, Brisbane, Qld, Australia
[4] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA
[7] Queensland Univ Technol, Princess Alexandra Hosp, Translat Res Inst, Brisbane, Qld, Australia
[8] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
[9] Univ Western Australia, Sch Med, Perth, WA, Australia
[10] Univ Western Australia, Natl Ctr Asbestos Related Dis, Perth, WA, Australia
[11] Univ Western Australia, Natl Ctr Asbestos Related Dis, Nedlands, WA, Australia
[12] North Shore Hlth Hub, Genesis Care, Sydney, NSW, Australia
[13] Johns Hopkins Kimmel Canc Ctr, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA
[14] Univ Chicago, Chicago, IL 60637 USA
[15] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[16] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[17] Emory Univ Hosp, Winship Canc Inst, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8599
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma
    Fennell, Dean A.
    McDowell, Cliona
    Busacca, Sara
    Webb, Glen
    Moulton, Brian
    Cakana, Andrew
    O'Byrne, Kenneth J.
    Meerbeeck, Jan V.
    Donnellan, Paul
    McCaffrey, John
    Baas, Paul
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : 1466 - 1470
  • [32] STELLAR - Interim Results of a Phase 2 Trial of TTFields with Chemotherapy for First Line Treatment of Malignant Mesothelioma
    Grosso, Federica
    Madrzak, Jarek
    Ramlau, Rodryg
    Cedres Perez, Susana
    Crino, Lucio
    Chella, Antonio
    Mencoboni, Manlio
    Hiddinga, Birgitta
    Ceresoli, Giovanni
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S329 - S329
  • [33] Caspian: Os Results from a Randomised Phase 3 Study of First-Line Durvalumab ± Tremelimumab plus Chemotherapy in ES-SCLC
    Reinmuth, Niels
    Paz-Ares, Luis
    Chen, Yuanbin
    Hotta, Katsuyuki
    Trukhin, Dmytro
    Statsenko, Galina
    Hochmair, Maximilian J.
    Ozguroglu, Mustafa
    Li, Jun Ho
    Voitko, Oleksandr
    Poltoratskiy, Artem
    Ponce, Santiago
    Verderame, Francesco
    Havel, Libor
    Bondarenko, Igor
    Kazarnowiczw, Andrzej
    Losonczy, Gyorgy
    Conev, Nicolay V.
    Armstrong, Jon
    Byrne, Natalie
    Shire, Norah
    Jiang, Haiyi
    Goldman, Jonathan
    Alt, Juergen
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 115 - 115
  • [34] UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial
    Haakensen, Vilde Drageset
    Ojlert, Asa Kristina
    Thunold, Solfrid
    Farooqi, Saima
    Nowak, Anna K.
    Chin, Wee L.
    Grundberg, Oscar
    Szejniuk, Weronika Maria
    Cedres, Susana
    Sorensen, Jens Benn
    Dalen, Tonje Sofie
    Lund-Iversen, Marius
    Bjaanaes, Maria
    Helland, Aslaug
    EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [35] Raltitrexed and oxaliplatin as first line treatment of advanced pleural mesothelioma. Preliminary data of a phase II study.
    Maisano, R
    Caristi, N
    Toscano, G
    Gnani, A
    Amadio, P
    Mare, M
    Munao, S
    La Torre, F
    ANNALS OF ONCOLOGY, 2000, 11 : 110 - 110
  • [36] Tumor Treating Fields plus chemotherapy for first-line treatment of malignant pleural mesothelioma: Final Results of the STELLAR Trial
    Ceresoli, G.
    Aerts, J.
    Madrzak, J.
    Dziadziuszko, R.
    Ramlau, R.
    Cedres, S.
    Hiddinga, B.
    Van Meerbeeck, J. P.
    Mencoboni, M.
    Planchard, D.
    Chella, A.
    Krzakowski, M.
    Crino, L.
    Grosso, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (01): : 230 - 231
  • [37] Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma
    Fennell, DA
    Steele, JPC
    Shamash, J
    Sheaff, MT
    Evans, MT
    Goonewardene, TI
    Nystrom, ML
    Gower, NH
    Rudd, RM
    LUNG CANCER, 2005, 47 (02) : 277 - 281
  • [38] Radiological Response Patterns in Malignant Pleural Mesothelioma (MPM): Subgroup Analyses of the Phase 2 Stellar Trial of TTFields Plus Chemotherapy for First-Line Treatment
    Grosso, F.
    Ceresoli, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S147 - S148
  • [39] First-Line Durvalumab plus Tremelimumab vs Platinum-Based Chemotherapy for Advanced/Metastatic NSCLC: Phase 3 NEPTUNE Study
    Mok, Tony
    Schmid, Peter
    De Castro, Gilberto, Jr.
    Syrigos, Kostas
    Martin, Claudio
    Yamamoto, Nobuyuki
    Aren, Osvaldo
    Arrieta, Oscar
    Gottfried, Maya
    Jazieh, Abdul Rahman
    Ramlau, Rodryg
    Timcheva, Constanta
    Trani, Leonardo
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1084 - S1084
  • [40] A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol
    Fujimoto, Nobukazu
    Aoe, Keisuke
    Kozuki, Toshiyuki
    Oze, Isao
    Kato, Katsuya
    Kishimoto, Takumi
    Hotta, Katsuyuki
    CLINICAL LUNG CANCER, 2018, 19 (05) : E705 - E707
12345